Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Cannabis Bioscience International Holdings (CBIH) Return on Sales (2022 - 2026)

Cannabis Bioscience International Holdings filings provide 5 years of Return on Sales readings, the most recent being 9.28% for Q1 2026.

  • On a quarterly basis, Return on Sales rose 88.0% to 9.28% in Q1 2026 year-over-year; TTM through Feb 2026 was 4.31%, a 343.0% decrease, with the full-year FY2025 number at 1.84%, up 16.0% from a year prior.
  • Return on Sales reached 9.28% in Q1 2026 per CBIH's latest filing, down from 1.86% in the prior quarter.
  • The five-year high for Return on Sales was 0.24% in Q2 2024, with the low at 10.16% in Q1 2025.
  • A 5-year average of 4.13% and a median of 3.24% in 2022 define the central range for Return on Sales.
  • Year-over-year, Return on Sales soared 619bps in 2024 and then tumbled -704bps in 2025.
  • Year by year, Return on Sales stood at 2.66% in 2022, then soared by 44bps to 1.48% in 2023, then surged by 38bps to 0.92% in 2024, then crashed by -102bps to 1.86% in 2025, then tumbled by -399bps to 9.28% in 2026.
  • Per Business Quant, the three most recent readings for CBIH's Return on Sales are 9.28% (Q1 2026), 1.86% (Q4 2025), and 3.81% (Q3 2025).